<li id="omoqo"></li>
  • <noscript id="omoqo"><kbd id="omoqo"></kbd></noscript>
  • <td id="omoqo"></td>
  • <option id="omoqo"><noscript id="omoqo"></noscript></option>
  • <noscript id="omoqo"><source id="omoqo"></source></noscript>
  • 發布時間:2019-04-23 17:33 原文鏈接: CriticalAppraisaloftheMTTAssayinthePresenceofRottlerin4

    Table 1 MTT reduction normalized to cell number

    Time (h)

    MTT/cell number

    R5

    R20

    1

    1.23

    1.54

    2

    1.20

    1.53

    4

    1.20

    1.70

    15

    1.25

    2.24

    24

    1.58

    3.49

    The MTT (% control)/cell number (% control) ratio was calculated in the samples treated with 5 and 20 μM Rottlerin (R5 and R20, respectively) at the indicated time points

    As shown in Fig. 3 , an overestimation of the MTT assay with respect to cell number was also observed in HMVEC, after a 24-h treatment with 20 μM Rottlerin.

    MediaObjects/12575_2009_9020_Fig3_HTML.gif

    Fig. 3 Effect of Rottlerin on HMVEC cell number and viability assessed by direct cell counting and MTT assay, respectively. HMVEC were treated with 20?μM Rottlerin (R20) before adding MTT. a Twenty-four hours later, cell number was determined, and b cell viability was measured as described in “Materials and methods”. Results are expressed as % of the control (100%). Values are the average of three separate experiments in quadruplicate and are expressed as mean?±?SD. *p?<?0.05.


    LDH assay in the presence of Rottlerin

    As shown in Table 2 , the kinetic of NADH oxidation by LDH is unchanged in the presence of 5 (not shown) and 20 μM Rottlerin with respect to the control, as it results from the very similar ΔA at the different times, although the absolute optical densities (OD; unchanged in the presence of 5 μM Rottlerin) are higher in the presence of 20 μM Rottlerin due to its intrinsic absorbance at 340 nm. Anyway, LDH activity and quantification are not altered by Rottlerin, the spectrophotometric interference of which does not invalidate LDH quantification.

    Table 2 LDH absorbance changes at 340 nm as a function of time in the presence or absence of Rottlerin

    Time

    DMSO

    20 μM Rottlerin

    OD

    ΔA

    OD

    ΔA

    30 s

    1.248


    1.365


    1.5 min

    1.211

    0.037

    1.320

    0.045

    2.5 min

    1.180

    0.031

    1.296

    0.024

    3.5 min

    1.147

    0.033

    1.262

    0.034

    4.5 min

    1.122

    0.025

    1.222

    0.040

    Mean ΔA/min

    0.031


    0.035


    LDH (U/l)

    503


    568


    The values reported in the table are representative of two LDH assays in the same sample and conditions

    Rottlerin effect on the energy charge


    相關文章

    190億!賽默飛收購歐洲IVD巨頭

    近日,服務科學領域的全球領導者賽默飛世爾科技(以下簡稱賽默飛)宣布,在達成收購意向兩個月之后,賽默飛以28億美元、折合人民幣約190億元的價格,完成了對TheBindingSiteGroup的全現金收......

    安捷倫宣布推出AssayMAPBravo蛋白質樣品前處理Workbench4.0

    將 AssayMAP 的使用范圍擴展至法規監管環境2022年11月28日,北京——安捷倫科技有限公司(紐約證交所:A)近日宣布推出AssayMAPBravo蛋白質樣品前處理Work......

    施普林格·自然與TheLens達成合作

    11月15日,施普林格·自然和TheLens平臺宣布結成重要的合作伙伴關系,以更深入地揭示學術研究和數據如何能通過經濟和社會成效,加速推動創新的問題解決方式。通過將科學、投資和企業領域的開放數據更好地......

    上交大發布全國首個MTT項目課程體系

    10月7日,上海交通大學中銀科技金融學院以線上線下結合形式,舉辦“科金創享”產教融合發展論壇暨上海交大技術轉移碩士(MTT)項目發布。MTT項目課程發布上海交大供圖“上海交大設立全國首個技術轉移專業碩......

    “3CoinONE全新體驗氣袋進樣器”ANTOP獎進入專家評審階段

    萬物蓬勃的7月里迎來了2022年ANTOP獎的申報和評審工作。由島津企業管理(中國)有限公司申報的“3CoinONE全新體驗氣袋進樣器”ANTOP獎進入專家評審階段。獎項名稱:3CoinONE全新體驗......

    青源峰達太赫茲在國際頂級期刊《TrendsinBiotechnology》發文

    青島青源峰達太赫茲科技有限公司研發團隊在國際頂級期刊《TrendsinBiotechnology》(譯名:《生物技術趨勢》)在線發表題為“THzmedicalimaging:frominvitroto......

    科學家將人工智能技術成功用于蛋白質復合物結構預測

    蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......

    發力癌癥分子病理診斷,無錫臻和全資收購TissueofOrigin?

    2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......

    這3個雜志撤回中國學者249篇文章,包含上交、中山等名校

    2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......

    firstinclass胃癌一線療法獲FDA突破性療法

    安進宣布,美國FDA授予其在研firstinclass單抗bemarituzumab突破性療法認定,與改良FOLFOX6化療方案(亞葉酸鈣、氟尿嘧啶和奧沙利鉑)聯用,一線治療FGFR2b過表達和HER......

    <li id="omoqo"></li>
  • <noscript id="omoqo"><kbd id="omoqo"></kbd></noscript>
  • <td id="omoqo"></td>
  • <option id="omoqo"><noscript id="omoqo"></noscript></option>
  • <noscript id="omoqo"><source id="omoqo"></source></noscript>
  • 1v3多肉多车高校生活的玩视频